Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar
He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.